Dexmedetomidine Facilitate Analgesia

• Status: Completed
• Trial end date: 2021-08-03
• Target enrollment: 0
• Participant gender: All

Summary

Pre-clinic evidences showed that DEX produces antinociception by inhibiting the activation of spinal microglia and astrocyte decreasing noxious stimuli evoked release of nociceptive substances and further interrupting the spinal neuron-glia cross talk and regulating the nociceptive transmission under chronic pain condition. in this study, the analgesic efficacy of Dexmedetomidine was evaluated by a new non-invasive nociceptive index (qNOX). In this study, Anagel6000 analgesia monitor was used to quantitatively compare the analgesic efficacy of Dexmedetomidine compared with Midazolam.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: China International Neuroscience Institution
• Treatments: Dexmedetomidine; Midazolam

Criteria

Inclusion Criteria:

• aged from 18 to 80 years old

• American Association of anesthesiologists (ASA) grade Ⅱ ~ IV

• body mass index (BMI) 18.5-40

• planning undergoing peripheral nerve block

Exclusion Criteria:

• incomplete effect of nerve block

• Alzheimer's disease

• implanted cardiac pacemakers

• mental illness

• epilepsy

• autonomic nervous system diseases

• projected the duration of the operation was more than 3 hours